This study is currently not recruiting participants.

A Phase 1a/1b Open Label Dose-escalation Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

The purpose of this study is to determine the dose of INCB052793 that is safe and tolerable in subjects with advanced cancer and to select the doses that will be studied further, and to assess the safety of INCB052793 in combination with gemcitabine and nab-paclitaxel in subjects with advanced solid tumors.

Description

The purpose of this study is to determine the dose of INCB052793 that is safe and tolerable in subjects with advanced cancer and to select the doses that will be studied further, and to assess the safety of INCB052793 in combination with gemcitabine and nab-paclitaxel in subjects with advanced solid tumors.

Details
Condition Advanced Malignancy
Age 100years or below
Clinical Study IdentifierTX4799
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.